The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index; none of the 200 sources its claims cite is checked for support yet.
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Open accessAbstract
Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that soluble Aβ oligomers, rather than insoluble amyloid plaques, are the primary synaptotoxic agents causing early memory failure in Alzheimer’s disease. It synthesizes cell, animal, and human evidence linking oligomers to synaptic plasticity disruption, synapse loss, tau pathology, insulin resistance, and candidate therapeutic strategies.
Key findings
- Aβ oligomers inhibit long-term potentiation (LTP) within minutes without affecting baseline excitability, and memory loss in APP transgenic mice can be reversed by anti-Aβ antibodies without removing amyloid plaques.
- Oligomers accumulate in AD-affected human brain and in essentially all transgenic AD models examined; synthetic and brain-derived oligomers show biochemical identity, and oligomer size remains debated (dimers–tetramers vs. 12mers/24mers), with SDS-stable 12mers linked to memory failure in one model.
- Oligomers target synapses: >90% co-localization with post-synaptic marker PSD-95; 50–85% of hippocampal neurons bind oligomers while others are spared; binding is associated with tau hyperphosphorylation, insulin receptor redistribution, spine loss, and oxidative stress.
- AD is discussed as a brain-specific form of diabetes (“type 3 diabetes”): Aβ oligomers induce insulin resistance, and intranasal insulin improves cognition in early AD at higher doses, consistent with insulin resistance.
Methods
- Narrative review of the literature, not a primary experimental study; it synthesizes findings from cell biology, animal models, human AD brain/CSF, and human genetics.
- Evidence discussed includes synthetic and brain-derived Aβ oligomers, transgenic mouse/rat/C. elegans/Drosophila models, electrophysiology (LTP/LTD), imaging, biochemical assays, and human clinical/ biomarker studies.
- Main analysis is qualitative synthesis; Tables 2 and 3 summarize synapse-specific and more generalized neuronal effects of Aβ oligomers.
Limitations
- Stated: the pathogenic oligomer size is uncertain; detection is limited by SDS-PAGE/Western blot, antibody choice, heat denaturation, and detergent; not all oligomers are toxic; nomenclature is confusing; why toxic oligomers accumulate in sporadic AD is largely unknown; intracellular vs. extracellular localization is unresolved; PrPC involvement is debated; synthetic oligomers can clump at high concentrations.
- Stated: published studies use different oligomer preparations, concentrations, incubation times, brain regions, and culture maturation stages, complicating comparison.
- Evident: as a narrative review, it lacks a systematic search strategy, formal quality appraisal, or meta-analysis, and presents an author-framed argument favoring the oligomer hypothesis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 200 cited sources checked · 0 supported · 0 flagged
In the paper
“A classic study by Terry, Masliah and colleagues subsequently confirmed that synapse loss is the best pathological correlate of Alzheimer’s dementia (Terry et al., 1991).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Terry et al., 1991 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Amyloid in fact is a poor correlate of disease state in AD models as in humans (Terry et al., 1991),”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Terry et al., 1991 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Dot immunoblots of soluble extracts from human brain show major increases in oligomers in AD-affected tissue (Gong et al., 2003; Kayed et al., 2003; Lambert et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Most importantly, these amyloid-free Aβ oligomers were potent CNS neurotoxins.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Its clinical relevance has been established by evidence that equivalent oligomers accumulate in AD-affected human brain and animal AD models.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIn the paper
“Mucke and colleague found that synapse loss does not require the presence of amyloid deposits (Mucke et al., 2000).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Mucke et al., 2000 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Recent findings by Bateman and colleagues show that clearance of Aβ in AD patients is reduced by 30% (Mawuenyega et al., 2010).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites Mawuenyega et al., 2010 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Recent evidence suggests that insulin resistance, a hallmark of diabetes, develops in Alzheimer’s brains (, 2000; Craft et al., 1999; de la Monte, 2009; Moroz et al., 2008; Pedersen and Flynn, 2004; Razay and Wilcock, 1994; Watson and Craft, 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In hippocampal slices, synthetic oligomers cause rapid LTP inhibition (Barghorn et al., 2005; Fa et al., 2010; Jurgensen et al., 2011; Lambert et al., 1998; Nimmrich et al., 2008; Rammes et al., 2011; Wang et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“At the cellular level, deficient insulin signaling results in impaired removal of Aβ (Plum et al., 2005) and Aβ oligomers from the extracellular milieu (Zhao et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 69
- Probably not a substantial claim. 20
In the paper
“Dodart, Paul and colleagues found that memory loss was reversed in APP tg-mice injected with antibodies against Aβ and that this reversal, moreover, did not require removal of amyloid plaques (Dodart et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Dodart et al., 2002 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Investigation into the action of clusterin by Lambert, Klein and colleagues established that, concomitant with inhibition of amyloid formation, clusterin promotes accumulation of soluble Aβ oligomers (Lambert et al., 1998).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“some neuropathologists rejected the hypothesis, emphasizing that a poor correlation exists between plaque load and cognitive function (Terry et al., 1994).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
What the sources say
- Not checked yetcites Terry et al., 1994
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true.
In the paper
“With chronic exposure, neurons ultimately were killed. Death was selective for subpopulations of vulnerable neurons and was prevented by knockout of Fyn, a protein tyrosine kinase linked to NMDA receptor signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on a central role for impaired signaling, the oligomer hypothesis predicted that early memory loss should be reversible. This prediction was confirmed in the transgenic mouse experiments mentioned above (Dodart et al., 2002; Kotilinek et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“oligomers were found to inhibit functional synaptic plasticity (Lambert et al., 1998). Long-term potentiation (LTP) was inhibited within minutes. This rapid loss of LTP, measured in rat brain slices and in situ in mice, occurred without impact on baseline excitability, indicating impairment of signaling rather than degeneration.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At present it is uncertain whether one class is more germane to pathogenesis than another.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Remarkably, at sub-nanomolar doses, the effect on LTP is reversed, and Aβ markedly enhances LTP. Discovered by Arancio and colleagues in a detailed analysis (Puzzo et al., 2008), enhancement occurs over a narrow range of concentrations and is associated with presynaptic activation of alpha7 nicotinic receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
- Not checked yetcites Puzzo et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“And in fact, not all oligomers are toxic, even those oligomers of a given size. Subtle conformation changes affect toxicity and immunoreactivity (Chromy et al., 2003; Pitt et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Traumatic brain injury also is associated with acutely elevated levels in CSF, with a positive correlation between oligomer levels and severity of sequelae (David Brody, MP Lambert, and WL Klein, unpublished).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites David Brody, MP Lambert, and WL Klein, unpublished
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In FAD, metabolic effects of mutations promote increased levels of total Aβ, or increased Aβ42 to Aβ40 ratio (Borchelt et al., 1996; Citron et al., 1992), conditions that favor oligomerization.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“More generalized neuronal impacts of Aβ oligomers (Table 3) include Ca2+ dyshomeostasis, oxidative stress and mitochondrial damage, proteasome inhibition, tau accumulation and hyperphosphorylation, impairment of fast axonal transport, ER stress, inhibition of the proteasome, cell cycle re-entry and, ultimately, cell death.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The discovery that memory failure in tg mice coincides with the appearance of SDS-stable 12mers is compelling in situ evidence that this species is pathogenic (Lesne et al., 2006).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
- Not checked yetcites Lesne et al., 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Relative levels of Aβ42 to Aβ40 appear to influence the mechanism of oligomerization, with higher levels of Aβ40 in normal individuals likely impeding formation of stable toxic oligomers (Giuffrida et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites Giuffrida et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Tg-mouse AD models manifest a spontaneous age-onset impairment of LTP (Gong et al., 2004) that presumably is linked to impaired performance in memory tests (Arendash et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Synapse-specific effects of Aβ oligomers (Table 2) include alterations in neurotransmitter (glutamate/D-serine) levels, down-regulation (due to abnormal trafficking or degradation) of plasticity-related receptors at the plasma membrane, altered plasticity (inhibition of long term potentiation and/or facilitation of long term depression), cytoskeletal abnormalities and synapse loss.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Memory loss, beginning early in the disease, was attributed to oligomer-induced disruption of synaptic plasticity, with later stages of dementia attributed to oligomer-induced cellular degeneration and death.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses.”
- Also stated in: § Abstract · plain
“We summarize here why attention has shifted away from amyloid plaques as the toxic agents of AD to the contemporary concept that memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
- Also stated in: § Abstract · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The conclusion that Aβ oligomers can be neurologically significant toxins, possibly the most important ones for AD, is now supported by more than a decade of further investigation, with over 1,000 papers addressing the oligomer hypothesis.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it now appears the most pathogenically relevant Aβ-derived toxins are small soluble oligomers, not readily detected.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
In the paper
“The hypothesis attributed dementia to nerve cell death caused by the toxicity of large insoluble amyloid fibrils.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
What the sources say
- Not checked yetcites Hardy and Higgins, 1992 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In conclusion, besides directly affecting memory-related processes, the various impacts of Aβ oligomers on neurons have the potential to account for major facets of AD neuropathology (e.g., tau hyperphosphorylation, oxidative stress, synapse loss), supporting the concept that Aβ oligomers provide a unifying mechanism for initiation of AD pathogenesis.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Serine phosphorylation precludes tyrosine phosphorylation of IRS-1, blocking downstream insulin signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Physiologically, IRS-1 is phosphorylated at tyrosine residues by the tyrosine kinase activity of the IR, which activates downstream signaling in the insulin pathway (Araki et al., 1994; White, 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“IRs are present in the brain, where they are abundantly distributed in synaptic membranes of the cerebral cortex and hippocampus (Abbott et al., 1999; Havrankova et al., 1981; Marks et al., 1990; Unger and Betz, 1998).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Aβ oligomers induce a striking redistribution of IRs, causing their internalization from dendritic membranes and accumulation in the cell body. This renders neurons insulin resistant (De Felice et al., 2009; De Felice et al., 2008; Zhao et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Brain insulin signaling declines with age (Frolich et al., 1998; , 1999; Hoyer, 1998; Rivera et al., 2005), the primary risk factor for AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“an elevated risk for AD also exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling (Matsuzaki et al., 2010; Ott et al., 1999; Toro et al., 2009; Watson and Craft, 2003), likely as a consequence of decreased insulin uptake into the brain following sustained peripheral hyperinsulinemia (Gerozissis et al., 1993; Kaiyala et al., 2000; Schwartz et al., 1990).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Internalization occurs by a mechanism mediated by casein kinase 2 (CK2) and Ca2+/calmodulin-dependent kinase 2 (CaMK II), which also are involved in ADDL-induced internalization of NMDA receptors (De Felice et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites De Felice et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
- Not checked yetcites Lacor et al., 2004 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, physiological insulin signaling may play an important role in defending neurons against AD, suggesting the loss of CNS insulin signaling in aging and diabetes is a potential risk factor for AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“When given to subjects with early AD, intranasal insulin also improves performance (Reger et al., 2008b) but only at higher doses, consistent with expected insulin resistance and suggesting possible involvement of additional mechanisms other than stimulation of plasticity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites Reger et al., 2008b
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Aβ oligomers induce a marked removal of IRs from synapses, decreasing the responsiveness of nerve cells to insulin.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The insulin-sensitizing drug rosiglitazone, a PPAR-γ agonist, potentiates the ability of insulin to protect synapses against Aβ oligomers, while a cell-permeant inhibitor of the tyrosine kinase activity of the IR abrogates the protection by insulin.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of IRs and synapse loss (De Felice et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites De Felice et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the ability of antibodies to reverse intracellular tau and synapse pathology (Chauhan et al., 2008; Oddo et al., 2006) and to provide cognitive benefits (Hillen et al., 2010; Takamura et al., 2011).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“stimulation of insulin signaling also protects against accumulation of hyperphosphorylated tau (Escribano et al., 2010), a pathological hallmark of AD that is induced by Aβ oligomers (De Felice et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The mechanism of protection does not involve direct competition between Aβ oligomers and insulin for a common binding site on the neuronal surface. Rather, it consists of an IR signaling-dependent down-regulation of neuronal ADDL binding sites.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clustering of oligomers at synapses, moreover, shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies. AD type tau hyperphosphorylation (De Felice et al., 2008), redistribution of insulin receptors (De Felice et al., 2009; Zhao et al., 2008), spine loss (Lacor et al., 2007) and oxidative stress (De Felice et al., 2007; Decker et al., 2010a) are manifest exclusively in”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, the peri-somatic distribution in human brain is evident in the complete absence of amyloid plaques, indicating oligomer pathology occurs early in the disease process.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As expected, the pattern of binding depends on cell maturation.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These oligomer-targeted neurons are distributed sparsely, indicating oligomers might originate within the cells they surround (Figure 1, right).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It can be concluded that oligomers are gain-of-function pathogenic ligands that target and disrupt signaling at particular synapses, a specificity that may explain why early AD is a disease of memory.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Lauren et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Significantly, some neurons are targeted while others are not, establishing clear-cut specificity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“EphB2 receptors interact functionally and physically with NMDARs at synapses”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other putative receptors/co-receptors involved in neuronal binding of Aβ oligomers include the p75 neurotrophin receptor (p75NTR) (Knowles et al., 2009), the receptor for advanced glycation end products (RAGE) (Sturchler et al., 2008), nicotinic acetylcholine receptors (Magdesian et al., 2005) and Frizzled (Magdesian et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggest that ADDL binding to synapses may involve the assembly of a multi-protein receptor whose assembly is promoted by NMDARs and likely involves other participants, including PrPC.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These observations indicate that NMDARs are necessary but not sufficient for ADDL binding”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This suggests that initial ADDL binding recruits more PrPC molecules (presumably by exocytosis of vesicles located proximal to the plasma membrane; (Caetano et al., 2011)) to form a higher order complex that may initiate toxic signaling at”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Caetano et al., 2011 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“NMDARs co-immunoprecipitate with Aβ oligomers from detergent-extracted oligomer-treated rat synaptosomal membranes, and an N-terminal anti-NR1 antibody markedly reduced oligomer binding to dendrites (De Felice et al., 2007).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites De Felice et al., 2007 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“NMDAR knock-down also abrogates neuronal oxidative stress induced by Aβ oligomers, which is mediated by aberrant activation of NMDARs (De Felice et al., 2007).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites De Felice et al., 2007 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A second prediction based on altered Arc expression is that oligomers would induce aberrant dendritic spine morphology, and this also has been confirmed in culture and in situ (Lacor et al., 2007; Ma et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Lacor et al., 2007 source
- Not checked yetcites Ma et al., 2009
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although receptors are lost from the surface, total levels are at first unchanged, indicating dysfunctional trafficking”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“What emerges from current evidence is that Aβ oligomers first bind to the neuronal plasma membrane at freely moving receptors, but lateral diffusion leads to interactions between Aβ oligomers and membrane proteins such as mGluR5 that ultimately target Aβ oligomers to synaptic sites.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Initially, Aβ oligomers diffused as if bound to an untethered protein. Within minutes, however, movement slowed and oligomers became immobilized, typically at active synapses labeled with FM4-64. The synaptic trapping of oligomers was accompanied by co-clustering and immobilization of mGluR5 metabotropic glutamate receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Renner et al., 2010 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Within minutes of exposure to oligomers, neurons show a localized over-expression of Arc, which later spreads ectopically throughout the dendrite.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Arc is an immediate early gene product that is translated from mRNA in dendritic spines (Bramham, 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Bramham, 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The mechanism of oligomer synapto-toxicity appears to be tied closely to accumulation of excessive levels of Ca++ (Marx, 2007), consistent with involvement of NMDA and mGluR5 receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Marx, 2007 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interaction with Aβ oligomers could potentially dysregulate such signaling pathways, resulting in neurotoxicity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“PrPC has been proposed to act as a cell-surface platform that orchestrates several physiological signaling pathways at the neuronal plasma membrane (for reviews, see (Linden et al., 2008; Martins et al., 2010)).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Linden et al., 2008 source
- Not checked yetcites Martins et al., 2010
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The consequent chronic mGluR5 activity would keep FMRP dephosphorylated and eliminate the ability of FMRP to repress mRNA translation.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Such aberrant spines also are seen in traumatic brain injury and prionoses (Fiala et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Fiala et al., 2002 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Fragile X also leads to hyperactivity in the protein phosphatase PP2a (Kim et al., 2008) which inactivates MAPK, an enzyme with impaired activity in oligomer-exposed neurons (Tong et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hyperactivity of mGluR5 receptors caused by oligomers is due to a clustering mechanism, as described earlier, and this receptor state hypothetically could be insensitive to negative feedback by FMRP.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Spines after short-term exposure to oligomers are long and spindly, resembling immature spines that express low levels of AMPA-Rs, as found early in development.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In the absence of FMRP, mGluR5 is hyperactive, with the consequences detailed above, and mGluR5 antagonists have been suggested as an approach to Fragile X treatment.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“This mechanism is in many respects analogous to the clustering of receptors at immunological synapses during T cell activation (Douglass and Vale, 2005), with the fundamental difference that oligomer-induced clustering is toxic.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Douglass and Vale, 2005
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Its control of Arc is a prime example (Iacoangeli et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
- Not checked yetcites Iacoangeli et al., 2008 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Eventually, spines deteriorate and synapses are lost, consistent with low levels of Arc found in mature tg-mice (Chin et al., 2005).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Chin et al., 2005 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Additional synaptic pathologies instigated by oligomers also are present in Fragile X, including aberrant spine morphology, loss of NMDA and AMPA receptors, and elevated LTD (Bear et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
- Not checked yetcites Bear et al., 2004 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Fragile X is a developmental disorder caused by inability to express the regulatory protein FMRP.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Another actin binding protein found in spines, drebrin, also becomes greatly diminished in culture (Lacor et al., 2007) and in tg-mice (Calon et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clustering can be elicited by mGluR5 antibodies, and antibody-induced clustering mimics the effects of oligomers in causing elevated Ca++ and synapse deterioration.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“there is also reason to believe that non-pharmacological approaches based on these novel findings might be beneficial to ameliorate AD symptoms (Schaeffer et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
- Not checked yetcites Schaeffer et al., 2009 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For example, exercise and a balanced diet might have positive effects on both peripheral and brain insulin signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One of the implications of this finding is that D1/D5 receptors may constitute a target for the development of novel approaches to combat synapse failure in AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In particular, the discovery that insulin resistance plays an important role in the pathogenesis of AD suggests that strategies aimed to bolster brain insulin signaling might be beneficial in preventing synapse failure and neuronal damage in AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“dopaminergic neurotransmission, centrally implicated in the brain reward system and known to decline with aging (De Keyser et al., 1990), plays important roles in non-pharmacological strategies aimed to improve age-related cognitive decline, such as environmental enrichment and physical exercise (van Praag et al., 2000).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Oligomer-induced hyperactivity of mGluR5 in Alzheimer’s disease would thus promote production of even more Aβ and oligomers.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“a connection has recently been established between dopaminergic signaling and AD, with demonstration that selective activation of D1/D5 dopamine receptors prevents pathological changes in synapse composition and function (including inhibition of LTP) induced by Aβ oligomers (Jurgensen et al., 2011).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
- Not checked yetcites Jurgensen et al., 2011 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
“the symptom that first brings patients to a physician is a troubling inability to form new memories, and early AD is largely regarded as a disease of memory formation.”
The paper relies on this without support.
AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
“This article reviews progress in the search for primary AD-causing toxins.”
“If we could regard AD as having a single disease-initiating cytotoxin (albeit one likely elicited by multiple factors), its action minimally must provide a basis for memory dysfunction.”
The authors state this as an assumption.
Aβ oligomers act from the extracellular milieu.
“A premise for investigating the effects of exogenous oligomers on memory and neuropathology is that oligomers presumably act from the extracellular milieu.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, the production of Aβ is a complex process and accumulating evidence indicates that soluble Aβ oligomers, not Aβ plaques alone, are the disease-causing species that induce substantial neurotoxicity including synaptic dysfunction and behavioral impairment [see review in Ref. (138)].”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [138]
In the citing paper
“In vivo and in vitro studies support a direct relationship between OS and synaptic dysfunction in AD [18,86,87,88,89,90].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [88]
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPratchayasakul, W., Kerdphoo, S., Petsophonsakul, P., Pongchaidecha, A., Chattipakorn, N., & Chattipakorn, S. C. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.02.003 · Cited by 206
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Flagged first, then by citations
5 of the 286 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Self-citationBomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 849
Self-citationRajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 730
Felice, F. G. D., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 676
Self-citationAmyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
Self-citationHalf a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 577
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
“Rather than considering that the unreliability of plaque as a disease marker may reflect badly on the amyloid hypothesis, its guardians embraced soluble Aβ oligomers as a cause of AD [100].”
BackgroundDanysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
“…deposits, are primarily responsible for both the neurodegeneration and especially the impairment of synaptic function in AD (Barghorn et al., 2005; Ferreira et al., 2007; 2011; Lacor et al., 2007; Parsons et al., 2007; Demuro et al., 2010; Xia, 2010; Ferreira and Klein, 2011; Wilcox et al., 2011).”
BackgroundFreiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., Felice, F. G. D., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 477
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 501
Synaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony
Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430
Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny‐Germano, L., Batista, A. F., Sathler, L. B., Brito‐Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 430
Self-citationThe amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
“…as reduction or abolition of long term potentiation (LTP); the injection of oAb into rodent brains to induce impaired cognitive functioning (Haass and Selkoe 2007; Ferreira and Klein 2011; Koffie et al. 2011; Mucke and Selkoe 2012; Hayden and Teplow 2013; Hefti et al. 2013; Viola and Klein 2015).”
BackgroundThe Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
“they have never been proven in AD patients [5-7].”
BackgroundThe Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 390
“However, during the last two decades it has also become recognized that soluble Aβ oligomers (AβOs) are toxic to synapses (Lambert et al., 1998; Walsh et al., 2002; Ferreira and Klein, 2011; Benilova et al., 2012; Mucke and Selkoe, 2012; Lesne et al., 2013).”
BackgroundFerreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
“In the following sections, we review multiple synaptotoxic/neurotoxic effects of AβOs, which led to the proposal of an ‘‘Aβ oligomer hypothesis’’ of AD (Ferreira and Klein, 2011) in an attempt to better explain how oligomer accumulation in the brain leads to memory decline and cognitive dysfunction in AD.”
BackgroundInfluentialSelf-citationInflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 363
Self-citationSilva, N. M. L. E., Gonçalves, R. A., Pascoal, T. A., Lima‐Filho, R. A. S., Resende, E. D. P. F., Vieira, É. L. M., Teixeira, A. L., de Souza, L. C., Peny, J. A., Fortuna, J. T. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01349-z · Cited by 364
Self-citationNew Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 362
“In 2011, Ferreira officially proposed the “Aβ oligomer pathogenic theory,” suggesting that soluble Aβ oligomers are the initiating factors leading to a series of pathological changes in AD (30).”
BackgroundHow does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Self-citationAlzheimer’s disease and insulin resistance: translating basic science into clinical applications
Felice, F. G. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 336
Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313
“Unfortunately, while the “Oligomer Hypothesis” is still a matter of investigation, and data are being gathered to test the grounds of its premises, the clinical failure of most of the anti-A (cid:2) drugs has strongly destabilized this concept.”
The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease
Forny‐Germano, L., Felice, F. G. D., & Vieira, M. N. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01027 · Cited by 307
“…that accumulate in AD brains, target synapses impairing synaptic function and plasticity and causing synapse loss (reviewed in Lambert et al., 1998; Ferreira and Klein, 2011; Forny-Germano et al., 2014) Aβ oligomers inhibit LTP and promote LTD of hippocampal synapses in vitro and in vivo (Wang et…”
BackgroundSynaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
“Upon binding to neurons, Aβ triggers the increase of extracellular D-serine, probably through alanine–serine–cysteine transporter 1 (asc-1) at the presynaptic terminal (Ferreira & Klein, 2011; Martineau, Parpura, & Mothet, 2014).”
BackgroundAmyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
“A oligomers (A O) appear to be the most neurotoxic species, triggering various processes that underlie AD, including synaptic dysfunction, impairment of long-term potentiation (LTP), Ca(2) dysregulation, mitochondrial dysfunction, endoplasmic reticulum stress, and the activation of pro-apoptotic pathways leading to ce…”
BackgroundGoozee, K. G., Shah, T. M., Sohrabi, H. R., Rainey‐Smith, S. R., Brown, B. M., Verdile, G., & Martins, R. N. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515004687 · Cited by 260
Alzheimer's Disease-Like Pathology Induced by Amyloid-β Oligomers in Nonhuman Primates
Forny‐Germano, L., Silva, N. M. L. E., Batista, A. F., Brito‐Moreira, J., Gralle, M., Boehnke, S. E., Coe, B. C., Lablans, A., Marques, S. A., Martinez, A. M. B., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1353-14.2014 · Cited by 245
“A s, synaptotoxins that accumulate in AD brains, have been implicated in key aspects of AD (DaRochaSouto et al., 2011; Ferreira and Klein, 2011; Selkoe, 2011; Chabrier et al., 2012; Finch and Austad, 2012).”
BackgroundSelf-citationThe role of endoplasmic reticulum stress in neurodegenerative disease
Xiang, C., Wang, Y., Zhang, H., & Han, F. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1296-4 · Cited by 235
d-serine levels in Alzheimer’s disease: implications for novel biomarker development
Madeira, C., Lourenco, M. V., Vargas-Lopes, C., Suemoto, C. K., Brandão, C. O., Reis, T., Leite, R. E. P., Laks, J., Jacob-Filho, W., Pasqualucci, C. A., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.52 · Cited by 239
Self-citationCell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles
Andrade-Moraes, C. H., de Oliveira-Pinto, A. V., Castro-Fonseca, E., da Silva, C. G., Guimarães, D. M., Szczupak, D., Parente-Bruno, D. R., Carvalho, L. R. B., Polichiso, L., Valério‐Gomes, B., et al. (2013) · Brain · doi:10.1093/brain/awt273 · Cited by 223
“…explanations have been proposed, such as a synaptic attack by amyloid-b oligomers (Gong et al ., 2003; Lacor et al ., 2004; Vieira et al ., 2007; Ferreira and Klein, 2011; Sebollela et al ., 2012), and tau hyperphosphorylation (De Felice et al ., 2008; Jin et al ., 2011; Flunkert et al .,…”
de Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
“Considerable evidence supports a central role of A Os in triggering harmful events that initiate neuronal oxidative stress and synapse damage leading to cognitive decline in AD (5, 30).”
BackgroundSelf-citationKanaan, N. M., Pigino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., & Morfini, G. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.003 · Cited by 215
“…list of potential mechanisms by which aggregated Aβ species, particularly oAβ, promote neuronal degeneration involve the induction of synaptic dysfunction (Ferreira and Klein, 2011, Moreno, et al., 2009) and promotion of FAT impairments through abnormal activation of kinases (Pigino, et al., 2009).”
BackgroundClarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214
“…studies have shown that soluble amyloid-b peptide oligomers (AbOs), toxins that build up in AD brains and have been proposed to be major players in synapse failure in AD (reviewed in Ferreira & Klein, 2011; Selkoe, 2011; Mucke & Selkoe, 2012), are linked to impaired hippocampal insulin signaling.”
BackgroundSelf-citationChallenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 213
“However, the complete identity of receptors to which they bind and the underlying signaling pathways still remain to be fully elucidated (Ferreira et al., 2015).”
BackgroundInfluentialTowards non-invasive diagnostic imaging of early-stage Alzheimer's disease
Viola, K. L., Sbarboro, J., Sureka, R., De, M., Bicca, M. A., Wang, J., Vasavada, S. R., Satpathy, S., Wu, S., Joshi, H. M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.254 · Cited by 196
Self-citationMadeira, C., Vargas-Lopes, C., Brandão, C. O., Reis, T., Laks, J., Panizzutti, R., & Ferreira, S. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00561 · Cited by 195
Self-citationGoure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“uble Aβ oligomers to be the most toxic Aβ form, causing both acute synaptotoxicity and inducing neurodegenerative processes [5-10,99-102].”
BackgroundCalcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 194
“Moreover, several studies demonstrated that Aβ oligomers have a key role in synaptic dysfunction and neuronal alterations [67–70], leading to cognitive impairment many years before the formation of amyloid plaques and neuronal death [71,72].”
BackgroundFigueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A. S., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 186
“…recognized as key mediators of synaptic and cognitive dysfunction in Alzheimer’s disease (AD) (Ferreira et al., 2007; Haass and Selkoe, 2007; Ferreira and Klein, 2011; Benilova et al., 2012; Selkoe, 2012), the molecular identity and the mechanisms by which oligomers impact synapses and…”
BackgroundSelf-citationImpaired insulin signalling and allostatic load in Alzheimer disease
Felice, F. G. D., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 183
Self-citationBuccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179
Pereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171
“, 2003) and are increasingly considered major toxins leading to neuronal dysfunction in AD (Ferreira and Klein, 2011; Mucke and Selkoe, 2012; Hong et al., 2016).”
BackgroundSelf-citationDeregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Paula‐Lima, A. C., Brito‐Moreira, J., & Ferreira, S. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12304 · Cited by 170
“AbOs interact with a multi-protein receptor complex that includes NMDARs as a central component Considerable evidence indicates that neuronal surface proteins mediate the interaction of AbOs with synaptic membranes, acting as toxin receptors (reviewed in Ferreira and Klein 2011).”
BackgroundInfluentialSelf-citationDeregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer’s disease
Beck, S. J., Guo, L., Phensy, A. J., Tian, J., Wang, L., Tandon, N., Gauba, E., Lu, L., Pascual, J. M., Kroener, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11483 · Cited by 175
Petrov, D., Pedrós, I., Artiach, G., Sureda, F. X., Barroso, E., Pallàs, M., Casadesús, G., Beas-Zarate, C., Carro, E., Ferrer, I., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.004 · Cited by 163
The Toxicity and Polymorphism of β-Amyloid Oligomers
Huang, Y., & Liu, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124477 · Cited by 176
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice
Ledo, J. H., Azevedo, E. P., Clarke, J. R., Ribeiro, F. C., Figueiredo, C. P., Foguel, D., Felice, F. G. D., & Ferreira, S. T. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.168 · Cited by 156
Self-citationHamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 171
“The decreased autophosphorylation of the insulin receptor and the subsequent alteration of its downstream cascade could lead to synaptotoxicity by altering long-term potentiation and neuronal dysfunction, and consequently to memory impairment [26,40,149,173,180,181].”
BackgroundLong-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 158
“…2005; Steen et al. 2005; Craft 2007) is believed to be an early and progressive event that could explain in part the synaptic failure, cognitive decline and impaired Ab and tau protein homeostasis that characterise the disease (Ferreira and Klein 2011; Holscher 2011; O'Neill et al. 2012).”
Demeritte, T., Nellore, B. P. V., Kanchanapally, R., Sinha, S. S., Pramanik, A., Chavva, S. R., & Ray, P. C. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b03619 · Cited by 154
“clearly indicate that the β amyloid (1-42) separation efficiency is less than 3% when anti- β amyloid antibody was not conjugated with nanoplatform.”
InfluentialMicroglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
“…‘‘M2-like”) may promote neurogenesis, improve Ab clearance, and contribute to an overall lower level of neuroinflammation and release of neurotrophins, potentially beneficial in both AD and MDD. increasingly recognized as proximal neurotoxins in AD (Ferreira et al., 2007; Ferreira and Klein, 2011).”
BackgroundSelf-citationThe Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules
Linden, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00077 · Cited by 151
“PrPC is highly expressed in both the nervous and immune systems, as well as in other organs, but its functions are controversial.”
BackgroundKlein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 145
Self-citationFamily, N., Maillet, É. L., Williams, L. T. J., Krediet, E., Carhart-Harris, R. L., Williams, T. A., Nichols, C. D., Goble, D. J., & Raz, S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05417-7 · Cited by 145
Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease
O’Neill, C., Kiely, A. P., Coakley, M. F., Manning, S., & Long-Smith, C. M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120080 · Cited by 140
Ledo, J. H., Azevedo, E. P., Beckman, D., Ribeiro, F. C., Santos, L. E., Razolli, D. S., Kincheski, G. C., Melo, H. M., Bellio, M., Teixeira, A. L., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1269-16.2016 · Cited by 138
“…of the amyloid- peptide (A Os), toxins that accumulate in the AD brain and are thought to trigger synapse failure and memory loss, have been implicated in key aspects of the pathogenesis of AD (Ferreira and Klein, 2011; Selkoe, 2011; Mucke and Selkoe, 2012; Benilova and De Strooper, 2013).”
Self-citationBodart‐Santos, V., de Carvalho, L. R. P., de Godoy, M. A., Batista, A. F., Saraiva, L. M., Lima, L. G., Abreu, C. A., Felice, F. G. D., Galina, A., Méndez‐Otero, R., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1432-5 · Cited by 140
Self-citationOstapchenko, V. G., Chen, M., Guzmán, M. S., Xie, Y., Lavine, N. E., Fan, J., Beraldo, F. H., Martyn, A. C., Belrose, J. C., Mori, Y., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4081-14.2015 · Cited by 143
“…marked toxicity of A toward glutamate synapses (Lambert et al., 1998; Walsh et al., 2002; Lacor et al., 2007; Laurén et al., 2009; Ma et al., 2009; Ferreira and Klein, 2011), one particularly attractive candidate mechanism contributing to Ca2 dysregulation in AD is via NMDARs (De Felice et al.,…”
BackgroundHamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. G. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-40 · Cited by 138
“Discussion The neurodegeneration characteristic of AD is associated with Aβ oligomers, which bind to neuronal synapses to both alter synaptic signaling and promote synaptic loss [35-37].”
BackgroundCognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
Huber, C. M., Yee, C., May, T., Dhanala, A., & Mitchell, C. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170490 · Cited by 136
Findley, C. A., Bartke, A., Hascup, K. N., & Hascup, E. R. (2019) · ASN NEURO · doi:10.1177/1759091419855541 · Cited by 133
“Evidence shows that soluble Ab accumulation results in synaptic failure, potentially through modifications to the glutamatergic system (Walsh et al., 2002; Wang et al., 2002; Barghorn et al., 2005; Cleary et al., 2005; Selkoe, 2008; Ferreira and Klein, 2011; Wilcox et al., 2011).”
The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128
Majdi, A., Sadigh‐Eteghad, S., Aghsan, S. R., Farajdokht, F., Vatandoust, S. M., Abbas-Abad, A. N., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 130
Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer’s Therapy?
Vieira, M. N. N., Silva, N. M. L. E., Ferreira, S. T., & Felice, F. G. D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00007 · Cited by 123
Self-citationFelice, F. G. D., & Lourenco, M. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00094 · Cited by 122
“, 1998), and not necessarily the insoluble amyloid fibrils detected in senile plaques, promote direct damage to synapses, besides stimulating inflammatory response and cellular stress (Ferreira and Klein, 2011; Viola and Klein, 2015).”
BackgroundThe case for soluble Aβ oligomers as a drug target in Alzheimer's disease
Hefti, F. F., Goure, W. F., Jerecìć, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.002 · Cited by 122
Chou, Y., Sundman, M., That, V. T., Green, J., & Trapani, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101660 · Cited by 133
Kincheski, G. C., Valentim, I. S., Clarke, J. R., Cozachenco, D., Castelo-Branco, M. T. L., Ramos-Lobo, A. M., Rumjanek, V. M. B. D., Donato, J., De Felice, F. G., & Ferreira, S. T. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.04.007 · Cited by 117
“…evidence implicates AbOs in multiple pathological aspects of AD, including synapse loss, cognitive impairment, generation of reactive oxygen species and tau hyperphosphorylation (for reviews, see Ferreira et al., 2015; Ferreira and Klein, 2011; Mucke and Selkoe, 2012; Selkoe and Hardy, 2016).”
BackgroundSelf-citationDysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases
Purro, S. A., Galli, S., & Salinas, P. C. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt049 · Cited by 115
“Evidence from in vitro and in vivo studies indicates that soluble Ab aggregates like dimers, trimers, and different sized oligomers are the synaptotoxic species (Walsh and Selkoe, 2007; Ferreira and Klein, 2011; Larson and Lesne, 2012).”
BackgroundGonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2021) · Biomolecules · doi:10.3390/biom11050767 · Cited by 115
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking
Guntupalli, S., Widagdo, J., & Anggono, V. (2016) · Neural Plasticity · doi:10.1155/2016/3204519 · Cited by 110
Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease
Александровна, П. Е., Pchitskaya, E. I., & Борисович, Б. И. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7506 · Cited by 106
Neuman, K. M., Molina-Campos, E., Musial, T. F., Price, A. L., Oh, K.-J., Wolke, M. L., Buss, E. W., Scheff, S. W., Mufson, E. J., & Nicholson, D. A. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0848-z · Cited by 104
Gonçalves, F. Q., Lopes, J. P., Silva, H. B. L., Lemos, C., Silva, A. C., Gonçalves, N., Tomé, Â. R., Ferreira, S. G., Canas, P. M., Rial, D., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104570 · Cited by 106
Self-citationRyan, P., Patel, B., Makwana, V., Jadhav, H. R., Kiefel, M. J., Davey, A. K., Reekie, T. A., Rudrawar, S., & Kassiou, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00185 · Cited by 101
Guillot‐Sestier, M., Sunyach, C., Ferreira, S. T., Marzolo, M., Bauer, C., Thevenet, A., & Checler, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323626 · Cited by 103
Self-citationP‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 100
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 96
Nunes‐Tavares, N., Santos, L. E., Stutz, B., Brito‐Moreira, J., Klein, W. L., Ferreira, S. T., & Mello, F. G. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321448 · Cited by 96
Self-citationAmyloid-β Peptide Binds to Cytochrome C Oxidase Subunit 1
Hernández-Zimbrón, L. F., Luna‐Muñoz, J., Mena, R., Vázquez‐Ramírez, R., Kubli‐Garfias, C., Cribbs, D. H., Manoutcharian, K., & Gevorkian, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042344 · Cited by 93
Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease
Santos, L. E., & Ferreira, S. T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.016 · Cited by 93
Self-citationIslet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Fawver, J. N., Ghiwot, Y., Koola, C., Carrera, W., Rodriguez-Rivera, J., Hernandez, C. M., Dineley, K. T., Kong, Y., Li, J., Jhamandas, J. H., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141107124538 · Cited by 90
Lin, J., Yu, J., Zhao, J., Zhang, K., Zheng, J., Wang, J., Huang, C., Zhang, J., Yan, X., Gerwick, W. H., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6792543 · Cited by 93
“Although the mechanisms underlying the pathogenesis of AD are not clearly elucidated, recent studies suggested that soluble β-amyloid (Aβ) oligomers are the main neurotoxic species that induce neuronal death and oxidative stress at the early stage of this disease [2, 3].”
BackgroundBatista, A. F., Rody, T., Forny-Germano, L., Cerdeiro, S., Bellio, M., Ferreira, S. T., Munoz, D. P., & De Felice, F. G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02099-x · Cited by 91
Self-citationTherapeutic potential of mGluR5 targeting in Alzheimer's disease
Kumar, A., Dhull, D. K., & Mishra, P. S. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00215 · Cited by 93
“Mounting evidence indicates that the overproduction of Aβ and its aggregation in the brain is a primary cause of AD (Jarrett et al., 1993; Hardy and Selkoe, 2002; Walsh and Selkoe, 2004; Lesné et al., 2006; Ferreira and Klein, 2011).”
BackgroundBernardi, A., Frozza, R. L., Meneghetti, Hoppe, Battastini, A. M. O., Pohlmann, Guterres, S. S., & Salbego (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s35333 · Cited by 91
“Although the amyloid fibrils found in plaques (as used in our model system) were originally believed to be responsible for AD pathogenesis, recent evidence indicates that the primary neurotoxic species in AD may actually be soluble oligomers of Aβ.(35,36) Additionally, it appears unlikely that there are just one or tw…”
Endoplasmic Reticulum Dysfunction in Alzheimer’s Disease
Li, J., Yu, J., Jiang, T., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8695-8 · Cited by 86
The Prion Protein Ligand, Stress-Inducible Phosphoprotein 1, Regulates Amyloid-β Oligomer Toxicity
Ostapchenko, V. G., Beraldo, F. H., Mohammad, A. H., Xie, Y., Hirata, P. H. F., Magalhães, A. C., Lamour, G., Li, H., Maciejewski, A., Belrose, J. C., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3214-13.2013 · Cited by 87
“STI1 interferes with the A O–PrP C interaction A Os have been shown to interact with several synaptic molecules (Ferreira and Klein, 2011), but its interaction with PrP C is one of the best characterized.”
BackgroundSelf-citationMoreno-Castilla, P., Rodriguez-Duran, L. F., Guzman-Ramos, K., Barcenas-Femat, A., Escobar, M. L., & Bermudez-Rattoni, F. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.021 · Cited by 84
Mimura, Y., Nishida, H., Nakajima, S., Tsugawa, S., Morita, S., Yoshida, K., Tarumi, R., Ogyu, K., Wada, M., Kurose, S., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.003 · Cited by 86
Amyloid-β Oligomers Induce Differential Gene Expression in Adult Human Brain Slices
Sebollela, A. S., Freitas-Corrêa, L., de Oliveira, F. F., Paula-Lima, A. C., Saraiva, L. M., Martins, S. M., Mota, L. D. C., Torres, C., Alves‐Leon, S. V., de Souza, J. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.298471 · Cited by 90
Self-citationNiedowicz, D. M., Reeves, V. L., Platt, T. L., Köhler, K., Beckett, T. L., Powell, D. K., Lee, T., Sexton, T. R., Song, E. S., Brewer, L. D., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-64 · Cited by 85
Pitt, J. E., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 87
“The relationship between AβOs and CNS insulin signaling overall is surprisingly complex (Ferreira and Klein, 2011; De Felice, 2013).”
BackgroundSelf-citationBrito-Moreira, J., Lourenco, M. V., Oliveira, M. M., Ribeiro, F. C., Ledo, J. H., Diniz, L. P., Vital, J. F. S., Magdesian, M. H., Melo, H. M., Barros-Aragão, F., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761189 · Cited by 84
“A Os target synapses (8, 9) and interact with a number of synaptic membrane proteins putatively assembled into a supramolecular receptor complex (5).”
BackgroundSelf-citationVitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology
Moon, M., Song, H., Hong, H. J., Nam, D. W., Cha, M.-Y., Oh, M. S., Yu, J., Ryu, H., & Mook‐Jung, I. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.161 · Cited by 83
Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease
Oliveira, J. M., Costa, M. G. C., Cachide, M., Silva, O. A. B. D. C. E., & Henriques, A. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170176 · Cited by 84
Denver, P., & McClean, P. L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238608 · Cited by 89
“…(AβOs) have been included in more recent revisions of the amyloid cascade hypothesis (Klein et al., 2001; Hardy and Selkoe, 2002), suggesting that soluble AβOs, rather than larger fibrils or plaques, elicit synaptic toxicity and memory dysfunction (Ferreira and Klein, 2011; Gulisano et al., 2018).”
BackgroundDefective proteostasis in Alzheimer’s disease
Cozachenco, D., Ribeiro, F. C., & Ferreira, S. T. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101862 · Cited by 87
Self-citationTherapeutic role of rifampicin in Alzheimer's disease
Yuluğ, B., Hanoğlu, L., Ozansoy, M., Isık, D., Kılıç, Ü., Kılıç, E., & Schabitz, W. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12637 · Cited by 81
“More generally, it has already been revealed that Aβ oligomers initiate several neuropathological processes involving the axonal dysfunction, tau hyperphosphorylation, dysregulation of Ca homeostasis, oxidative stress, mitochondrial damage, energy depletion, endoplasmic reticular stress, proteasome inhibition, cell cy…”
BackgroundResultZimbone, S., Monaco, I., Gianì, F., Pandini, G., Copani, A. G., Giuffrida, M. L., & Rizzarelli, E. (2018) · Aging Cell · doi:10.1111/acel.12684 · Cited by 79
“Specifically, soluble A b oligomers are fundamental to promote neurotoxicity (Klein, 2001; Walsh & Selkoe, 2007) through different ways (Ferreira & Klein, 2011; Pearson-Leary & McNay, 2012), including altered levels of neurotrophic factors (NTFs) (Calissano et al. , 2010; Budni et al. , 2015).”
Metadata
- Authors
- Ferreira, S. T., & Klein, W. L.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Northwestern University (US)
- Corresponding author
- Klein, William L.
- Venue
- Neurobiology of Learning and Memory
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 96
- Issue
- 4
- Pages
- 529-543
- ISSN
- 1074-7427 (ISSN-L)
- PMC
- PMC4390395
- OpenAlex
- W2051268743
- Cited by
- 442
- References
- 286
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 22 · 2023: 24 · 2022: 37 · 2021: 28 · 2020: 35 · 2019: 23 · 2018: 44 · 2017: 41 · 2016: 33 · 2015: 35 · 2014: 38 · 2013: 24 · 2012: 26
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Learning and Memory (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG022547, R01AG029460, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, memory loss, amyloid plaques, pathogenesis, diabetes mellitus, fragile X syndrome, animal models of Alzheimer's disease, Alzheimer's disease treatment
- MeSH terms
- Alzheimer Disease, Brain, Humans, Memory Disorders, Neurons, Synapses, Amyloid beta-Peptides, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
